KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Gains from Sales and Divestitures (2018 - 2022)

Vir Biotechnology's Gains from Sales and Divestitures history spans 5 years, with the latest figure at $349496.0 for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures rose 291.54% year-over-year to $349496.0; the TTM value through Dec 2022 reached $349496.0, up 291.54%, while the annual FY2022 figure was $349496.0, 291.54% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $349496.0 at Vir Biotechnology, up from $216886.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.2 million in Q4 2018 and bottomed at $52963.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $618079.0 (2020), against an average of $981317.1.
  • The largest annual shift saw Gains from Sales and Divestitures crashed 92.9% in 2021 before it skyrocketed 309.5% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $2.2 million in 2018, then decreased by 11.63% to $2.0 million in 2019, then fell by 9.79% to $1.8 million in 2020, then crashed by 95.02% to $89261.0 in 2021, then surged by 291.54% to $349496.0 in 2022.
  • Per Business Quant, the three most recent readings for VIR's Gains from Sales and Divestitures are $349496.0 (Q4 2022), $216886.0 (Q1 2022), and $89261.0 (Q4 2021).